Business & Consumer Services » Business Services | Interpace Diagnostics Group Inc.

Interpace Diagnostics Group Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
150,842.00
119,935.00
9,432.00
13,085.00
15,897.00
21,896
Cost of Goods Sold (COGS) incl. D&A
143,837.00
116,979.00
10,722.00
10,411.00
10,611.00
13,449
Gross Income
7,005.00
2,956.00
1,290.00
2,674.00
5,286.00
8,447
SG&A Expense
11,282.00
14,340.00
27,672.00
17,613.00
18,681.00
19,044
EBIT
4,277.00
11,384.00
28,962.00
14,939.00
13,395.00
10,597
Unusual Expense
-
2,086.00
11,446.00
8,497.00
2,824.00
1,522
Non Operating Income/Expense
59.00
68.00
93.00
14.00
2,128.00
263
Interest Expense
-
602.00
3,705.00
2,144.00
433.00
331
Pretax Income
4,336.00
14,140.00
44,206.00
8,572.00
13,132.00
12,187
Income Tax
180.00
4,738.00
13,136.00
162.00
395.00
18
Consolidated Net Income
4,516.00
9,402.00
31,070.00
8,410.00
12,737.00
12,205
Net Income
4,516.00
9,402.00
31,070.00
8,410.00
12,737.00
12,205
Net Income After Extraordinaries
4,467.00
2,731.00
50,784.00
8,488.00
13,258.00
12,221
Net Income Available to Common
4,565.00
16,073.00
32,990.00
9,658.00
12,216.00
12,189
EPS (Basic)
3.10
10.80
7.30
4.59
0.77
0.43
Basic Shares Outstanding
1,471.80
1,490.10
1,547.50
1,816.00
15,766.00
28,155
EPS (Diluted)
3.10
10.79
7.34
4.59
0.77
0.43
Diluted Shares Outstanding
1,471.80
1,490.10
1,547.50
1,816.00
15,766.00
28,155
EBITDA
2,852.00
8,993.00
23,932.00
10,669.00
9,705.00
7,133

About Interpace Diagnostics Group

View Profile
Address
Morris Corporate Center 1
Parsippany New Jersey 07054
United States
Employees -
Website http://www.interpacediagnostics.com
Updated 07/08/2019
Interpace Diagnostics Group, Inc. is an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.